Buy & Sell Vanguard Real Estate Index Fund ETF (VNQ) – Vanguard Real Estate Index Fund ETF Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Sector
- -9.31%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 84% Buy | 16% SellTrading Activity
- 95 daysTypical Hold Time
Over the past 52 weeks, Vanguard Real Estate Index Fund ETF has traded between a low of $87 and a high of $97.09, highlighting its annual price range. Over the past three months, Vanguard Real Estate Index Fund ETF has recorded a drawdown of -9.31%, reflecting recent price volatility. On average, investors hold Vanguard Real Estate Index Fund ETF for approximately 95 days, indicating typical investor behavior on the platform.
About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Most Recent News
State Street Global Advisors buys 3,532 shares in DCC plc, raising stake to 1.39%
State Street Global Advisors & Affiliates purchased 3,532 ordinary shares of DCC plc on May 19, 2026, at a price of €59.90 per share. This transaction increased their total holding to 1,189,358 shares, representing 1.3923% of the company's shares. Th...

Stellantis plans Europe JV to sell Dongfeng EVs, plus new affordable EV launch in 2028.
Stellantis and Dongfeng signed a non-binding Memorandum of Understanding to create a Europe-based joint venture focused on sales, distribution, and engineering of Dongfeng's new energy vehicles (NEVs). The JV, majority-owned by Stellantis, will launc...

Cell-based therapies advance with Avaí Bio's α-Klotho cell bank milestone, boosting anti-aging and neurodegenerative treatment prospects.
Avaí Bio and Austrianova have completed a Master Cell Bank of genetically modified cells overexpressing the α-Klotho protein, a key anti-aging factor, marking a major step toward clinical trials for cell-based therapies targeting aging and related di...
